NTRA - Natera, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
14.71
+0.10 (+0.68%)
As of 9:52AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close14.61
Open14.65
Bid14.61 x 1400
Ask14.75 x 1300
Day's Range14.55 - 14.75
52 Week Range7.78 - 14.99
Volume9,961
Avg. Volume172,401
Market Cap801.88M
Beta2.03
PE Ratio (TTM)N/A
EPS (TTM)-2.53
Earnings DateAug 6, 2018 - Aug 10, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.25
Trade prices are not sourced from all markets
  • PR Newswireyesterday

    Natera and Institut Jules Bordet Announce Collaboration in Neoadjuvant Breast Cancer

    Signatera assay to be used in research to evaluate treatment response and minimal residual disease SAN CARLOS, Calif. , June 19, 2018 /PRNewswire/ --  Natera, Inc. , (NASDAQ: NTRA), a global leader in ...

  • PR Newswire7 days ago

    Natera Announces New Clinical Utility Data and Issuance of CPT Code for NIPT in Twin Pregnancies

    SAN CARLOS, Calif., June 13, 2018 /PRNewswire/ -- Natera (NTRA), a leader in genetic testing and cell-free DNA analysis, announces that the American Medical Association has issued a new CPT code for zygosity testing in twin pregnancies. Natera has generated new utility data2 from an analysis of the first 5,000 commercial zygosity cases processed by Natera since its launch of the Panorama zygosity test in 2017: more than 1 in 4 clinicians marked that they were "unsure" – based on ultrasound alone – whether the babies shared a single placenta.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of NTRA earnings conference call or presentation 8-May-18 8:30pm GMT

    Q1 2018 Natera Inc Earnings Call

  • Associated Presslast month

    Natera: 1Q Earnings Snapshot

    On a per-share basis, the San Carlos, California-based company said it had a loss of 61 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...

  • PR Newswire2 months ago

    Natera Inc. Announces First Quarter 2018 Earnings Conference Call

    SAN CARLOS, Calif. , May 1, 2018 /PRNewswire/ --  Natera , (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will release results ...

  • GlobeNewswire2 months ago

    Research Report Identifies Cracker Barrel Old Country Store, Enova International, Natera, Inovalon, UMH Properties, and Progenics Pharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, May 01, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cracker ...

  • PR Newswire2 months ago

    Natera to Present Successful Results at AACR from Bladder and Colon Cancer Studies

    Performance Data for Treatment Monitoring, Recurrence Monitoring, and Staging at Diagnosis SAN CARLOS, Calif. , April 13, 2018 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing ...

  • PR Newswire2 months ago

    Natera To Present New Data at ACMG Annual Meeting

    Study results demonstrate value of SNP-based non-invasive prenatal testing, expanded carrier screening, and embryo and miscarriage tissue testing across various genetic conditions SAN CARLOS, Calif. , ...

  • PR Newswire2 months ago

    Natera Appoints Paul R. Billings, M.D., Ph.D., as Chief Medical Officer

    SAN CARLOS, Calif., April 9, 2018 /PRNewswire/ -- Natera (NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA (cfDNA), has appointed Paul R. Billings, M.D., Ph.D., as Chief Medical Officer and Senior Vice-President of Medical Affairs to help lead its efforts across reproductive health, oncology, and new emerging businesses. "We are thrilled to have Dr. Billings join Natera," said Matthew Rabinowitz, Ph.D., Natera's CEO. "I am excited to join Natera at this time of rapid innovation and growth for the company," Dr. Billings said.

  • ACCESSWIRE3 months ago

    Wired News - Thermo Fisher Scientific Disclosed Plans to Build State-of-the-Art Pharma Services Facility in Germany

    Stock Monitor: Natera Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 20, 2018 / Active-Investors.com has just released a free research report on Thermo Fisher Scientific Inc. (NYSE: TMO ). If ...

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of NTRA earnings conference call or presentation 13-Mar-18 9:00pm GMT

    Q4 2017 Natera Inc Earnings Call

  • Associated Press3 months ago

    Natera reports 4Q loss

    On a per-share basis, the San Carlos, California-based company said it had a loss of 87 cents. Losses, adjusted for non-recurring costs, came to 73 cents per share. The genetic testing company posted revenue ...

  • PR Newswire3 months ago

    Natera Reports Fourth Quarter and Fiscal Year 2017 Financial Results

    SAN CARLOS, Calif. , March 13, 2018 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results ...

  • ACCESSWIRE3 months ago

    Natera, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 13, 2018 / Natera, Inc. (NASDAQ: NTRA ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 13, 2018, at 5:00 PM Eastern Time. To listen ...

  • QIAGEN Ties Up With Natera, Boosts GeneReader NGS Platform
    Zacks3 months ago

    QIAGEN Ties Up With Natera, Boosts GeneReader NGS Platform

    QIAGEN (QGEN) forges ahead with deals to strengthen the GeneReader NGS Platform.

  • PR Newswire3 months ago

    QIAGEN and Natera partner to develop cutting-edge genetic testing assays for use on QIAGEN's GeneReader NGS System

    Frankfurt Prime Standard: QIA), a world leader in providing Sample to Insight molecular solutions, and Natera, Inc. (NTRA), a leading developer of next-generation sequencing (NGS) assays that include non-invasive prenatal genetic testing and the analysis of circulating tumor DNA, today announced a partnership to develop cutting-edge, cell-free DNA assays for use on QIAGEN's GeneReader NGS System. Natera's Constellation™ software would also be accessible for users of these and other assays in combination with the QIAGEN Clinical Insights (QCI) bioinformatics solution.

  • Business Wire3 months ago

    QIAGEN and Natera Partner to Develop Cutting-Edge Genetic Testing Assays for Use on QIAGEN’s GeneReader NGS System

    QIAGEN N.V. , a world leader in providing Sample to Insight molecular solutions, and Natera, Inc. , a leading developer of next-generation sequencing assays that include non-invasive prenatal genetic testing and the analysis of circulating tumor DNA, today announced a partnership to develop cutting-edge cell-free DNA assays for use on QIAGEN’s GeneReader NGS System.

  • PR Newswire3 months ago

    Natera Inc. Announces Fourth Quarter and Fiscal 2017 Earnings Conference Call

    Natera Also Presenting at the 38th Annual Cowen Healthcare Conference SAN CARLOS, Calif. , March 7, 2018 /PRNewswire/ --  Natera, Inc. , (NASDAQ: NTRA), a leader in non-invasive genetic testing and the ...

  • PR Newswire4 months ago

    Natera's Genetic Tests Now Fully Integrated into Yale New Haven Health's Epic EMR System

    SAN CARLOS, Calif., March 5, 2018 /PRNewswire/ -- Natera, Inc., (NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that Yale New Haven Health has fully integrated the company's Panorama® non-invasive prenatal test (NIPT) and Horizon™ carrier screening test into its Epic electronic medical record (EMR) platform, making it easier for physicians to order and receive prenatal genetic testing information. According to Matthew Rabinowitz, Ph.D., Natera's CEO, this represents another integration for the company's genetic screening products. "We are pleased to integrate with Yale New Haven Health's Epic EMR system, making Natera's tests and patient results readily available to providers throughout its health system," Rabinowitz said.

  • PR Newswire5 months ago

    Natera To Feature Expanded Panorama® Non-Invasive Prenatal Test, Now Validated for Twin Pregnancies, at SMFM Annual Meeting

    SAN CARLOS, Calif., Jan. 29, 2018 /PRNewswire/ -- Natera (NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, will feature its recently expanded Panorama® non-invasive prenatal test (NIPT), which is now validated for screening twin pregnancies, at the Society for Maternal-Fetal Medicine (SMFM) Annual Meeting in Dallas, Jan. 29 to Feb. 3, 2018 (booth No. 161). Panorama® is the first NIPT that can screen twin pregnancies for zygosity (identical or non-identical twins) and determine gender for each twin as early as 9 weeks' gestation. It is the only NIPT that differentiates between maternal and fetal DNA, which enables women to learn more about their pregnancies through a simple blood draw from the mother, posing no risk to the babies.

  • PR Newswire5 months ago

    Natera To Webcast Live Presentation at the 36th Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2018

    SAN CARLOS, Calif., Jan. 8, 2018 /PRNewswire/ -- Natera (NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will webcast a live presentation at the 36th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Thursday, Jan. 11, 2018 at 9:00 a.m. Pacific Time. Natera CEO Matthew Rabinowitz will provide an overview of the company and its latest developments, followed by a question and answer session. COO Steve Chapman and CFO Mike Brophy will be available to answer questions.